Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-22

Clinical Trial Update: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase 2 trial of blinatumomab in relapsed/refractory B-precursor acute lymphoblastic leukemia completed; results were posted in January 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen Research (Munich) GmbH | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-01-22